Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADCY1 | Q08828 | 16/20 | 1.00 |
| ▸ | ADCY8 | P40145 | 6/20 | 0.78 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.67 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.67 |
| ▸ | RECQL | P46063 | 1/20 | 0.67 |
| ▸ | CCR6 | P51684 | 1/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.63 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17717053 | 0.93 | ADCY1 (0.86) | ADCY1ADCY8LMNAKDM4EOPRK1 | |
| SCHEMBL20598531 | 0.88 | ADCY1 (1.00) | ADCY1ADCY8LMNAKDM4EOPRK1 | |
| SCHEMBL17717010 | 0.87 | ADCY1 (1.00) | ADCY1ADCY8LMNAKDM4EOPRK1 | |
| SCHEMBL20598245 | 0.86 | ADCY1 (1.00) | ADCY1ADCY8LMNAKDM4EOPRK1 | |
| SCHEMBL20597987 | 0.82 | ADCY1 (1.00) | ADCY1ADCY8LMNAKDM4EOPRK1 | |
| SCHEMBL20582130 | 0.81 | ADCY1 (1.00) | ADCY1ADCY8LMNAKDM4EOPRK1 | |
| SCHEMBL20598199 | 0.81 | ADCY1 (1.00) | ADCY1ADCY8LMNAKDM4EOPRK1 | |
| SCHEMBL20598356 | 0.81 | ADCY1 (1.00) | ADCY1ADCY8LMNAKDM4EOPRK1 | |
| SCHEMBL20598390 | 0.81 | ADCY1 (1.00) | ADCY1ADCY8LMNAKDM4EOPRK1 | |
| SCHEMBL20598526 | 0.81 | ADCY1 (1.00) | ADCY1ADCY8LMNAKDM4EOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200031785-A1 | METHODS FOR TREATING CHRONIC PAIN AND OPIOID DEPENDENCE USING ADENYLYL CYCLASE INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2020-01-30 | — | — | US | disclosed |
| US-10457653-B2 | Adenylyl cyclase inhibitors for chronic pain and opioid dependence | PURDUE RESEARCH FOUNDATION (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190002418-A1 | ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | PURDUE RESEARCH FOUNDATION (US) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190002418-A1 | ADENYLYL CYCLASE INHIBITORS FOR CHRONIC PAIN AND OPIOID DEPENDENCE | CAP1, OPRK1, OPRL1 | ADCY1 4/4885ADCY8 13/4885LMNA 4818/4885 |
| US-10457653-B2 | Adenylyl cyclase inhibitors for chronic pain and opioid dependence | CAP1, ADCY1, OPRK1 | ADCY1 2/4885ADCY8 14/4885LMNA 4802/4885 |
| US-20200031785-A1 | METHODS FOR TREATING CHRONIC PAIN AND OPIOID DEPENDENCE USING ADENYLYL CYCLASE INHIBITORS | ADCY1, CAP1, ADCY2 | ADCY1 1/4885ADCY8 11/4885LMNA 4464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.